Recruiting

Testing two treatments to slow aging in healthy adults and cancer survivors

Plain-English translation of NCT07363057 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of two new medications—GI-102 and GIB-7—to see if they can help slow the aging process in your body. GI-102 works by boosting your immune system and reducing inflammation, while GIB-7 is a probiotic blend designed to support your gut health, muscle strength, and sleep-wake cycle. The study will measure whether this combination improves markers of aging in both healthy adults and people who have survived cancer.

As we age, our immune system weakens and inflammation builds up in our bodies, which contributes to age-related diseases. This medication combination is being tested to address these aging processes through two complementary approaches: reactivating the immune system while also supporting gut and muscle health.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you are in generally good health without life-threatening illness
if you have had cancer, you have been cancer-free for at least 2 years, or in remission for at least 12 months if diagnosed more recently
if you can have children, you agree to use effective contraception during the study and for several months after
you are able to walk and perform daily activities independently without a walker or wheelchair

You likely don't qualify if…

you have severe, poorly controlled chronic diseases such as advanced heart disease, kidney failure, uncontrolled diabetes, or severe lung disease
you currently depend on a walker or wheelchair or have severe difficulty with daily activities
you have had major surgery in the past 6 months or plan to have surgery during the study
you have a history of substance abuse or IV drug use in the past 5 years
you are pregnant, planning to become pregnant, or breastfeeding

What participation looks like

You will be randomly assigned to receive either the combination of both medications or a placebo (inactive treatment) for 8 weeks. You'll take the medications as directed and attend study visits where researchers will measure various aging-related markers in your blood and assess your strength and physical function. The study takes place over multiple countries and includes both healthy adults and cancer survivors.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(2 sites)

Australia

Novatrials, Charlestown, New South Wales

Southern Oncology Clinical Research Unit, Adelaide, South Australia